intensive insulin therapy

ApprovedSmall molecule

intensive insulin therapy is one of 101 small molecule programs targeting Diabetic Nephropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Ischemic StrokeActive, not recruiting

Diabetic NephropathyPhase 3

Active, not recruiting

Acute Myocardial InfarctionPhase 1

Active, not recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

intensive insulin therapy

NNorthwestern University

Approved

1 2

Repatha

Amgen

Preclinical

2 3

Proamatine

Takeda

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critically Ill Patients1 trial

Efficiency of Continuous Glucose Monitoring in Critically Ill Patients

Completed·MMedical University of Vienna·N/A·NCT00494078·120 enrolled

Steroid-Induced Diabetes1 trial

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

Enrolling by invitation·MMedical University of Warsaw·Phase 4·NCT07117240·100 enrolled

Ischemic stroke1 trial

Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

Unknown status·HHospital Sao Domingos·Phase 4·NCT00747279·70 enrolled

Stem Cell1 trial

Hematopoietic Stem Cell Support Versus Insulin in T1D

Withdrawn·NNorthwestern University·Phase 1/2·NCT01285934

Acute Myocardial Infarction1 trial

Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.

Completed·EEmory University·Phase 1·NCT00209144·58 enrolled

4 more indications

Diabetic Nephropathy1 trial

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

Unknown status·NNantes University Hospital·Phase 3·NCT01067950·180 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Frequently Modified Intensive Insulin

Completed·HHygieia, Inc·N/A·NCT01014832·14 enrolled

Diabetes1 trial

I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes

Completed·UUniversity Hospital, Grenoble·N/A·NCT00324792·45 enrolled

Unspecified1 trial

Tight Glycemic Control With Intensive Insulin Therapy in PICU

Unknown status·GGreet Van den Berghe·Phase 2·NCT00214916·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for intensive insulin therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intensive insulin therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intensive insulin therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNorthwestern University

intensive insulin therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critically Ill Patients1 trial

Steroid-Induced Diabetes1 trial

Ischemic stroke1 trial

Stem Cell1 trial

Acute Myocardial Infarction1 trial

Diabetic Nephropathy1 trial

Efficacy and Safety1 trial

Diabetes1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News